IRMD vs PHAR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IRMD presents a dichotomy between exceptional operational performance and extreme valuation premiums. While the Piotroski F-Score of 4/9 indicates stable financial health and the company boasts an impressive 76.75% gross margin and a consistent 25-quarter earnings beat record, the stock is trading significantly above its Graham Number ($17.07) and Intrinsic Value ($51.62). The strong fundamental growth is currently offset by bearish insider activity from the CEO and a completely bearish technical trend (0/100).
PHAR presents a stark contrast between fundamental value and growth momentum, anchored by a stable Piotroski F-Score of 4/9. While the company exhibits explosive earnings growth (104.2% YoY) and a perfect recent track record of earnings beats, it trades at an extreme premium with a P/E of 433.25 and a Price/Book of 41.46. The massive divergence between the current price ($17.33) and the Graham Number ($0.61) indicates the market is pricing in aggressive future expansion rather than current assets. Despite strong analyst optimism and a 'strong_buy' consensus, the razor-thin profit margin (0.76%) leaves the company vulnerable to operational volatility.
Compare Another Pair
Related Comparisons
IRMD vs PHAR: Head-to-Head Comparison
This page compares IRADIMED CORPORATION (IRMD) and Pharming Group N.V. (PHAR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.